title: Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients.
abstract: Sustained-release morphine (MST) given by the rectal route was compared with oral MST in an open randomised cross-over trial in ten patients with cancer who received stable doses of MST. No significant difference was found in the areas under the curve of the concentration-time profiles (AUC) following oral or rectal administration for parent morphine. The AUCs determined for morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) after oral administration were approximately twice those obtained following rectal administration. The maximal concentration achieved was lower and the time to maximal concentration was longer following rectal administration for morphine, M6G and M3G. The relative mean arrival times following rectal administration were significantly longer for morphine and M3G but not for M6G. These findings suggest slower absorption but less first-pass metabolism of MST after rectal administration. No significant difference was noted between the oral and the rectal route in measurements on visual-analogue scales for pain or side effects. We recommend the rectal route as being suitable for MST administration when the oral route is no longer available. In changing from oral to rectal administration, the same dose and dose interval may be used, but dose adjustment may be needed.
authors: Oncology Service, Christchurch Hospital, New Zealand.
authors: T J
authors: TJ
authors: Wilkinson
authors: B A
authors: BA
authors: Robinson
authors: E J
authors: EJ
authors: Begg
authors: S B
authors: SB
authors: Duffull
authors: P J
authors: PJ
authors: Ravenscroft
authors: J J
authors: JJ
authors: Schneider
mesh_terms: D000284:Administration, Oral; D000285:Administration, Rectal; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D009022:Morphine Derivatives / Q000097:blood; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D010146:Pain / Q000097:blood / Q000188:drug therapy*; D010147:Pain Measurement; D013997:Time Factors
chemical_list: D003692:Delayed-Action Preparations; D009022:Morphine Derivatives; C035349:morphine-6-glucuronide; D009020:Morphine; C018108:morphine-3-glucuronide